

May 23, 2023

Seiji Inagaki

Representative Director and Chair of the Board

Dai-ichi Life Holdings, Inc.

Partial Corrections to “Convocation Notice of the Annual General Meeting of Shareholders for the 13th Fiscal Year”

Dai-ichi Life Holdings, Inc. (the “Company”) announces the partial corrections to “Convocation Notice of the Annual General Meeting of Shareholders for the 13th Fiscal Year” dated May 15, 2023.

The Company extends its sincere apologies and makes the correction as shown below. The correction has been reflected in the documents currently released on the Company’s website and the Tokyo Stock Exchange’s website.

Portions subject to correction: General Description of Significant Parent Company and Subsidiaries, etc.(page 60)

(The underlined parts indicate the correction.)

(Before correction)					
General Description of Significant Parent Company and Subsidiaries, etc.					
(ii) Subsidiaries, etc.					
Company name	Location	Major business	Date of establishment	Capital	Percentage of voting rights of subsidiaries, etc. held by the Company
Dai-ichi Life Reinsurance Bermuda Ltd.	British Overseas Territory, Bermuda	Reinsurance business	September 25, 2020	US\$ <u>65</u> Million	100.0% (100.0%)
(After correction)					
General Description of Significant Parent Company and Subsidiaries, etc.					
(ii) Subsidiaries, etc.					
Company name	Location	Major business	Date of establishment	Capital	Percentage of voting rights of subsidiaries, etc. held by the Company
Dai-ichi Life Reinsurance Bermuda Ltd.	British Overseas Territory, Bermuda	Reinsurance business	September 25, 2020	US\$ <u>135</u> Million	100.0% (100.0%)

Portions subject to correction: Remuneration for Directors and Audit & Supervisory Committee Members (page 69)

(The underlined parts indicate the correction.)

(Before correction)
<p>•Remuneration for Directors and Audit & Supervisory Committee Members (iv) Remuneration (including performance-linked amount) for directors (excluding directors serving as Audit & Supervisory Committee members and outside directors)</p> <p>The Company's rating of company performance based on the following results was <u>III-</u> for the fiscal year ended March 31, 2021 (FY2020) and III for the fiscal year ended March 31, 2022 (FY2021).</p>
(After correction)
<p>•Remuneration for Directors and Audit & Supervisory Committee Members (iv) Remuneration (including performance-linked amount) for directors (excluding directors serving as Audit & Supervisory Committee members and outside directors)</p> <p>The Company's rating of company performance based on the following results was <u>III</u> for the fiscal year ended March 31, 2021 (FY2020) and III for the fiscal year ended March 31, 2022 (FY2021).</p>

Portions subject to correction: Remuneration for Directors and Audit & Supervisory Committee Members (page 70)

(The underlined parts indicate the correction.)

(Before correction)
<p>•Remuneration for Directors and Audit & Supervisory Committee Members (iv) Remuneration (including performance-linked amount) for directors (excluding directors serving as Audit & Supervisory Committee members and outside directors)</p> <p>The FY2020 performance ratings ranged from II to III-, and the FY2021 performance ratings were <u>III</u>.</p>
(After correction)
<p>•Remuneration for Directors and Audit & Supervisory Committee Members (iv) Remuneration (including performance-linked amount) for directors (excluding directors serving as Audit & Supervisory Committee members and outside directors)</p> <p>The FY2020 performance ratings ranged from II to III-, and the FY2021 performance ratings were <u>from II to III-</u>.</p>

Portions subject to correction: Remuneration for Directors and Audit & Supervisory Committee Members (page 71)

(The underlined parts indicate the correction.)

(Before correction)

•Remuneration for Directors and Audit & Supervisory Committee Members

(iv) Remuneration (including performance-linked amount) for directors (excluding directors serving as Audit & Supervisory Committee members and outside directors)

The performance evaluation period for the performance-linked stock-based remuneration shall be the three fiscal years from the year ended March 31, 2022 to the year ending March 31, 2025.

(After correction)

•Remuneration for Directors and Audit & Supervisory Committee Members

(iv) Remuneration (including performance-linked amount) for directors (excluding directors serving as Audit & Supervisory Committee members and outside directors)

The performance evaluation period for the performance-linked stock-based remuneration shall be the three fiscal years from the year ended March 31, 2023 to the year ending March 31, 2025.

Portions subject to correction: Remuneration for Directors and Audit & Supervisory Committee Members (page 71)

(The underlined parts indicate the correction.)

(Before correction)
<p>•Remuneration for Directors and Audit & Supervisory Committee Members</p> <p>(v) Total amount of remuneration for directors</p> <p>(Note 3) Stock remuneration, which is positioned as a non-monetary remuneration or a remuneration equivalent thereto, consists of a restricted stock remuneration of the Company for the purpose of boosting the directors' morale and desire to contribute to the enhancement of shareholder value of the Dai-ichi Life Group as a whole and promoting the sharing of value with shareholders, <u>the wholly-owning parent of the Company,</u> for as long as possible; and performance-linked stock-based remuneration of the Company as an incentive to enhance corporate value, that is linked to the level of achievement of performance indicators selected based on management objectives of the Dai-ichi Life Group, including the medium-term management plan.</p>
(After correction)
<p>•Remuneration for Directors and Audit & Supervisory Committee Members</p> <p>(v) Total amount of remuneration for directors</p> <p>(Note 3) Stock remuneration, which is positioned as a non-monetary remuneration or a remuneration equivalent thereto, consists of a restricted stock remuneration of the Company for the purpose of boosting the directors' morale and desire to contribute to the enhancement of shareholder value of the Dai-ichi Life Group as a whole and promoting the sharing of value with shareholders for as long as possible; and performance-linked stock-based remuneration of the Company as an incentive to enhance corporate value, that is linked to the level of achievement of performance indicators selected based on management objectives of the Dai-ichi Life Group, including the medium-term management plan.</p>

End.